Bliss GVS Pharma Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, along with the declaration of an interim dividend. The pharmaceutical company's Board of Directors approved these results at their meeting held on February 10, 2026.

Financial Performance Overview

The company's financial performance for Q3FY26 showed mixed results across standalone and consolidated operations:

Nine-Month Performance

For the nine months ended December 31, 2025, the company demonstrated stronger performance:

On consolidated basis, nine-month revenue reached ₹67,011.96 lakh compared to ₹61,174.04 lakh in the previous year, while net profit increased to ₹9,772.90 lakh from ₹7,360.27 lakh.

Interim Dividend Declaration

The Board declared an interim dividend of 50%, equivalent to ₹0.50 per equity share of face value Re.1 each for financial year 2025-2026. Key dividend details include:

Exceptional Items and Labour Code Impact

The company recognized exceptional items of ₹251.37 lakh during Q3FY26 related to the implementation of New Labour Codes effective November 21, 2025. This amount represents incremental employee benefit obligations recognized as past service cost. The company continues monitoring the finalization of Central and State Rules for appropriate accounting treatment.

Business Expansion and Subsidiaries

Bliss GVS Pharma expanded its international presence through subsidiary incorporations:

• Theralife Pharma Ltd. incorporated in Republic of Kenya on November 25, 2025, through wholly-owned subsidiary Bliss GVS International Pte. Ltd., Singapore
• Theralife Pharma RDC Private Limited incorporated in Democratic Republic of Congo on January 27, 2026 (post quarter-end)

The company operates in a single segment of "Pharmaceutical and Healthcare" and allotted 4,18,700 equity shares during the nine months under its ESOP Scheme 2019, with 24,17,500 options remaining outstanding as of December 31, 2025.

Operational Metrics

Employee benefit expenses included share-based payment expense of ₹555.88 lakh for nine months ended December 31, 2025, compared to ₹342.04 lakh in the corresponding previous period. The company's paid-up equity share capital stood at ₹1,057.89 lakh as of December 31, 2025.

The financial results were subjected to limited review by statutory auditors Kalyaniwalla & Mistry LLP, who issued unmodified conclusion reports for both standalone and consolidated results.

Bliss GVS Pharma Limited has announced the incorporation of a wholly owned subsidiary in the Democratic Republic of Congo, marking another step in the company's international expansion strategy. The new subsidiary, THERALIFE PHARMA RDC PRIVATE LIMITED, was established in Kinshasa-Gombe through the company's existing Singapore operations.

Subsidiary Details and Structure

The incorporation was executed through Bliss GVS International PTE Ltd., Singapore, which is itself a wholly owned subsidiary of Bliss GVS Pharma Limited. This step-down subsidiary structure allows the company to expand its operations in the African pharmaceutical market.

Regulatory Compliance and Disclosure

The company has fulfilled its regulatory obligations by informing both the National Stock Exchange of India Ltd. and BSE Limited about this corporate development. The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key aspects of the regulatory filing include:

• Compliance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
• Adherence to SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023
• Complete disclosure as per Annexure-A requirements

Strategic Implications

The newly incorporated subsidiary operates within the pharmaceutical and health sector, aligning with Bliss GVS Pharma's core business activities. As this is a recent incorporation with a date of December 26, 2025, no turnover data is available for the entity. The establishment of this subsidiary demonstrates the company's commitment to expanding its presence in emerging African markets while maintaining its focus on the pharmaceutical industry.

The incorporation does not involve any acquisition costs or related party transactions, as it represents the creation of a new wholly owned subsidiary rather than the purchase of an existing entity. No governmental or regulatory approvals were required for this incorporation, and the process has been completed as announced.